At five-years post procedure, 67% of patients who required daily PPI’s prior to receiving Plicator treatment remained off daily PPI therapy and gastroesophageal reflux disease (GERD) HRQL scores remained significantly improved (10 versus 19 p< 0.001). In addition, 50% of patients experienced a greater than 50% improvement in their GERD HRQL scores while also experiencing no late occurring adverse events. Plicator therapeutic response at 5-years post-treatment was comparable to the outcomes observed at 3-years post-treatment, demonstrating stable reconstructive efficacy. Bernard Haffey, president and CEO of NDO, said: "Plicator is the most studied, most advanced endoluminal surgical device and procedure available to GERD patients and can be a long term alternative to daily PPI therapy."